



California Transparency in Supply Chains and UK Modern Slavery Act Statement

This statement is published in accordance with the U.K. Modern Slavery Act 2015 and the California Transparency in Supply Chains Act. It sets out the steps that BioMarin Pharmaceutical Inc. and its subsidiaries, including BioMarin (U.K.) Ltd., have taken during the financial year ending 31 December 2021 and will continue to take, to prevent slavery, child labor, and human trafficking in its business and supply chain. All references to BioMarin in this statement are references to BioMarin Pharmaceutical Inc. and its subsidiaries.

BioMarin has determined that it is not a Subject Entity under the requirements of the Australian Federal Modern Slavery Act and the New South Wales Modern Slavery Act.

About BioMarin

BioMarin is a multinational pharmaceutical company focused on creating therapies for rare and ultra-rare diseases. Founded in 1997, BioMarin is headquartered in San Rafael, California, and operates in over 70 countries with over 3,000 employees worldwide. In addition to its California headquarters, BioMarin has regional hubs and local offices in various locations globally.

BioMarin is committed to conducting its business in accordance with all legal and regulatory requirements and with the highest standards of ethical behaviour. For that reason, BioMarin maintains rigorous internal processes to follow laws, regulations, and industry codes of conduct that support good business practices.

Modern Slavery

BioMarin is committed to ensuring its supply chain and operations remain free from any form of human slavery, human trafficking, and forced labor. To this end, BioMarin continues to raise awareness among its employees, suppliers, partners, and other stakeholders on this critical topic.

Policies and Controls

BioMarin believes that its [Global Code of Conduct and Business Ethics](#) (Global Code of Conduct) establishes the principles and expectations of its employees and contractors. BioMarin enforces compliance with those expectations through internal audits, training, and, when necessary, disciplinary action. The scope of these principles includes adherence to applicable laws and fair and ethical business practices.

The clause on ethical business practices clearly states:

- [BioMarin] does not seek competitive advantages through illegal or unethical business practices. Each employee should endeavour to deal fairly with [BioMarin's] patients, customers, healthcare professionals, and employees, and other business associates. No employee should take unfair advantage of anyone through inappropriate manipulation, abuse of privileged information, misrepresentation of material facts, or any unfair dealing practice.

The Global Code of Conduct also directly states that BioMarin is committed to “complying with child labor laws and laws prohibiting any form of forced, bonded, or indentured labor or



involuntary prison labor.”

BioMarin requires its employees to report any policy or legal violations. Reports can be made via BioMarin’s reporting hotline, Ethics Point (<http://biomarin.ethicspoint.com>).

BioMarin's Global Compliance and Ethics (GCE) function is responsible for monitoring, investigating, and enforcing the Global Code of Conduct principles. GCE regularly reviews BioMarin’s policies, including the Global Code of Conduct, and revises them to reflect BioMarin’s position on ongoing issues. GCE provides regular reports on compliance issues to the CEO and Board of Directors.

BioMarin also has a Corporate Responsibility Committee (CRC), a cross-functional team that regularly tracks and reports on developments regarding human trafficking and slavery to an executive-level steering committee to ensure sufficient visibility into human rights issues. BioMarin requires its business partners to comply with all applicable laws, regulations, industry codes, and contractual terms.

Due Diligence

BioMarin understands that there is potential exposure to slavery, human trafficking, and forced labor when purchasing goods and services from third parties. To address this, BioMarin conducts regular GxP compliance audits of its materials and service providers as part of its overall commitment to the quality of the products we produce. BioMarin employs its own staff or contractors for these audits, and they are scheduled in advance. The scope of these supplier evaluations includes review of labor practices and documenting instances of deviations from legal or ethical standards established by the country of origin or by BioMarin.

BioMarin has not employed a third party to specifically evaluate and address risks of human trafficking and slavery in its supply chain. However, any business partners responsible for distribution or marketing on behalf of BioMarin must undergo a background check for due diligence purposes before being engaged.

BioMarin contracts with its materials and service providers and specifies within those contracts that compliance with all applicable laws is integral to performance under those contracts.

Assessing and Managing Modern Slavery Risk in BioMarin’s Supply Chain

BioMarin believes there is a very low risk its supply chain contains any element of slavery, child labor, or human trafficking due to the specialized and complex nature of producing BioMarin’s products. To the best of its knowledge, BioMarin does not source materials associated with forced labor or child labor as listed in the U.S. Department of Labor’s List of Goods Produced by Child Labor or Forced Labor (2020). BioMarin does not pursue a strategy of low-cost country sourcing and is foremost focused on quality and risk avoidance. Suppliers are closely monitored for many aspects of the production process including the caliber and training of the personnel employed.

Modern Slavery Training

All employees at BioMarin are required to annually certify that they have read, understand, and will comply with the BioMarin Global Code of Conduct, which covers topics such as slavery, human trafficking, and forced labor. In an effort to increase awareness and understanding of the issue of human trafficking and slavery, and to improve the ability to verify its absence from BioMarin’s supply chain, BioMarin has trained supply chain personnel



and supplier quality personnel. This training will be repeated periodically and will be documented in the personnel files of the employees.

Assessing and Managing Risk

BioMarin is committed to conducting its business in accordance with all legal and regulatory requirements and with the highest standards of ethical behavior. To this end, BioMarin has adopted corporate governance principles for business conduct and ethics to serve as a guide to help all BioMarin employees, directors, and BioMarin subsidiaries maintain the highest ethical and professional standards in the course of performing their job duties. Any questions or comments regarding BioMarin's business practices should be directed to BioMarin's Compliance and Ethics Hotline at <http://biomarin.ethicspoint.com> or by telephone at 1-866-513-7198 (USA) or 0808-234-9171 (UK).

BioMarin and Modern Slavery

BioMarin regularly reviews and update its policies, procedures, and guidelines, which includes efforts to raise awareness of human trafficking, forced labor, and slavery. BioMarin is dedicated to maintaining appropriate safeguards to protect human rights in its supply chain and business.

This statement was reviewed and approved by the Corporate Responsibility Committee Executive Committee in May 2022.

This statement was approved by the Board of Directors of BioMarin (U.K.) Ltd. on 17 May 2022.

DocuSigned by:

B91CCA99D7BA49F
Chay Morgan
VP, Regulatory Affairs, EMEA
BioMarin (U.K.) Ltd.

DocuSigned by:

F46C82F2FFB846F...
Richard Morris
VP, Legal and Compliance, EMEA
BioMarin (U.K.) Ltd.